Company profile
Bicycle Therapeutics
Bicycletx Limited is a UK company with status active founded in 2017 based in East of England.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
AA | Transaction MzUyNzQzMzU5NWFkaXF6a2N4 | Paper/PDF filed
Published 02 Jul 2026 05:29
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQzMTUxODY3MGFkaXF6a2N4
Published 07 Aug 2024 15:36
Company registered at Companies House
6 Jul 2024 to 6 Jul 2027
To transfer knowledge and techniques required to develop novel antibiotics. The KTP will focus on the development of methods to screen for new prototype antibiotics and apply the screens in the laboratory. The KTP brings together expertise in bacterial biology in the KB and expertise in drug discovery from industry.
1 Jun 2021 to 29 Feb 2024
The COVID-19 pandemic illustrates the need for future preparedness to tackle emerging infectious diseases. Whilst \>1 million people worldwide have died from COVID, antibiotic-resistant bacterial infections kill 700,000 people every year. COVID-19 has also exacerbated the AMR crisis by increasing use of broad-spectrum antibiotics, and also creating a rese...
1 Oct 2020 to 30 Apr 2021
Whilst the COVID-19 pandemic has caused the death of \>500,000 people worldwide this year, antibiotic-resistant bacterial infections are killing 700,000 people every year. The worldwide effort to develop new antibiotics has suffered severe dislocation during the COVID pandemic. Worse still COVID has increased use of broad-spectrum antibiotics due to the t...
1 Sep 2020 to 31 Dec 2021
Bicycles are a new class of drug that can rapidly be identified using our unique platform technology and have utility if they can be developed as novel anti-virals for use in tackling the current and/or future covid pandemics. They also have potential as novel anti-inflammatory therapies tailored to the requirements of later stage Covid-19 disease suffere...
1 Feb 2019 to 31 Mar 2020
Evolution of bicyclic peptides as penicillin binding protein inhibitors . Discovery of novel leads for new antibacterial drugs is a major challenge in the R&D process. It is often argued that the compound collections of pharmaceutical companies are focussed around mammalian targets and lack compounds with structural features typical of successful antibiot...
1 Sep 2018 to 31 Aug 2019
"Resistance to antibiotics is a major public health threat that could have huge impact on medicine and indeed our way of life. Reports have suggested that without substantial interventions, 100 million people could die from infection from antibiotic-resistant bacteria by 2050\. The issue is not just deaths from untreatable infection but the inability to c...
1 May 2013 to 31 May 2013
Awaiting Public Project Summary
